Quest Diagnostics reported its financial results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter (Q4), the company posted net revenues of USD 2.81 billion. Cost of services for the period totaled USD 1.90 billion, while selling, general and administrative expenses were USD 504 million. Net income attributable to shareholders for Q4 was USD 273 million, and diluted earnings per share $(EPS)$ reached USD 2.42, reflecting an 8.5 percent increase compared to the same period in the previous year. For the full year (FY) 2025, net revenues were USD 11.04 billion. Cost of services for the year amounted to USD 7.37 billion, and selling, general and administrative expenses totaled USD 1.97 billion. Net income attributable to shareholders for FY 2025 was USD 1.12 billion, with diluted EPS of USD 9.85, representing a 10.3 percent increase compared to the prior year. Quest Diagnostics continues to operate a network serving one in three adult Americans annually, supported by nearly 57,000 employees. The company also released its guidance for full year 2026 and additional details are available on its investor relations website. Management highlighted the ongoing complexity of billing, reimbursement, and the competitive environment as factors influencing performance, and advised stakeholders to review the company’s most recent filings for a comprehensive discussion of risks and future expectations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: NY83718) on February 10, 2026, and is solely responsible for the information contained therein.